Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Acquire Enzyme Engineering Firm Kapa Biosystems

NEW YORK (GenomeWeb) – Roche has signed a definitive agreement to acquire molecular biology enzyme firm Kapa Biosystems for an undisclosed amount, the company said today.

Kapa, headquartered in Wilmington, Massachusetts, with an R&D and manufacturing facility in Cape Town, South Africa, provides optimized enzymes for next-generation sequencing, PCR, and real-time PCR applications.

The company has a proprietary protein engineering technology to generate enzymes with improved performance for specific applications, including novel DNA polymerases for sequencing sample prep. Last month, for example, Kapa said it would supply library prep reagents for 10X Genomics' GemCode platform.

"This acquisition builds on Roche's commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution," said Roland Diggelmann, COO of Roche Diagnostics, in a statement, adding that it complements its existing NGS technology, such as target enrichment products.

The acquisition, which is subject to customary closing conditions, adds to other purchases by Roche in the areas of genomics and molecular diagnostics this year, including microbial diagnostics firm GeneWeave and cancer diagnostics companies CAPP Medical and Signature Diagnostics.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.